CJC-1295 Research Reference

Quick Facts

Best-Effort Research Profile

CJC-1295 is a modified human growth hormone-releasing factor 1-29 analog and growth hormone-releasing hormone agonist. In preclinical work, the peptide activated the growth hormone-releasing factor receptor and produced sustained plasma exposure after subcutaneous administration in rats. In a randomized, placebo-controlled human study, subcutaneous CJC-1295 produced dose-dependent increases in circulating growth hormone and insulin-like growth factor I in healthy adults.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Reported Research Effects

• Activates the growth hormone-releasing factor receptor in cultured rat anterior pituitary cells and in rats.
• In healthy adults, increased mean plasma growth hormone concentrations approximately 2- to 10-fold for 6 days or more after a single injection in the reported study.
• In healthy adults, increased mean plasma insulin-like growth factor I concentrations approximately 1.5- to 3-fold for 9 to 11 days after a single injection in the reported study.
• With repeated dosing in the reported human study, mean insulin-like growth factor I concentrations remained above baseline for up to 28 days.
• The U.S. FDA identifies limited clinical data and reports potential immunogenicity and peptide-characterization concerns for compounded CJC-1295, as well as serious adverse events including increased heart rate and systemic vasodilatory reaction.
• Listed by the World Anti-Doping Agency as a growth hormone-releasing hormone analog prohibited at all times.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Primary human evidence consists of randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults aged 21-61 years. The study used single subcutaneous doses and repeated weekly or biweekly subcutaneous dosing; the publication specifically discusses tolerability at 30 and 60 micrograms/kg. These are study-reference parameters, not recommended use instructions. Preclinical characterization identified CJC-1295 as a tetrasubstituted hGRF(1-29) analog with a C-terminal N-epsilon-3-maleimidopropionamide lysine derivative; an albumin-associated immunoreactive species was detected in rat plasma beyond 24 hours and the peptide was present beyond 72 hours.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 446262-90-4; PubChem CID 91971820; molecular formula C165H269N47O46; molecular weight approximately 3647.2 g/mol

Source-Backed Observations

This record is anchored to the albumin-binding maleimido CJC-1295 described in the primary literature and represented by PubChem CID 91971820. The unqualified name may be used inconsistently for related CJC-1295/GHRH-derived materials; DAC status and exact molecular identity should therefore be confirmed when comparing reference materials.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Related Research Articles

Published articles on this site that mention CJC-1295 or one of its catalog aliases.

Related Research Tools